We now report the ability of denosumab to efficiently target tumorsphere-initiating, RANKL-addicted CSC-like cells in cancer-prone BRCA1mut/+ breast epithelial cell populations, and also in the presence of key amplifiers of breast cancer CSC-like cellular states including EMT phenomena and HER2 activation. This evidence concerns the gene ERBB2 and breast carcinoma.